Patrik Gille-Johnson, MD
Patrik has been working as an MD Infectious Diseases Consultant at Danderyds Sjukhus AB and Karolinska Universitetssjukhuset for many years and has from this position gained a deep understanding of the challenges of antimicrobial resistance and the need for novel therapeutic options.
Annette Alaeus, MD-PhD
Annette is a highly experienced infection specialist and has worked as Medical Director at Bristol Myers Squibb. She is currently a Senior Consultant and a member of the Medical Quality Team at Kry, with particular involvement in their “Global Team Covid-19”.
Tomas N Gustafsson, MD-PhD
Tomas is a Physician at the Infectious Disease Clinic at Sunderby Hospital, Luleå, and a researcher at the Department of Clinical Microbiology, Umeå University. His primary research interest includes early antibiotic development as well as development of methods to help bridge gaps in the antibiotic development pipeline.
BOARD OF DIRECTORS
Prof. Elias S.J. Arnér, MD PhD Prof. Elias S.J. Arnér, MD PhD
Elias Arnér, MD PhD, was appointed Professor in Biochemistry in 2009 and in 2008 he succeeded Prof. Arne Holmgren as Head of the Biochemistry Division in the Department of Medical Biochemistry and Biophysics at Karolinska Institutet (KI). His PhD thesis (1993) was on nucleoside analogs as therapeutics and he did his first post doc (1993 to 1997) with Prof. Arne Holmgren on mammalian thioredoxin reductase as a selenoprotein, with a second post doc (1998 to 1999) with August Böck (Munich) on production of selenoproteins in E. coli. Studies of therapeutics, redox biology and selenoproteins continue to be the research topics in the Arnér laboratory. Arnér has published 150+ articles found in PubMed, with 18,500+ citations and an h-index of 59 (Google Scholar). As a world-renowned scientist in redox biology and biotechnological applications, and as the successor of Prof. Holmgren, his role as Scientific Advisor for Thioredoxin Systems AB helps to ensure a solid basis in redox biochemistry in the operations of the Company.
Peter Holm, PhD BOARD MEMBER
Peter Holm is a European Patent Attorney, Partner and country manager for Sweden at the patent law firm HØIBERG. He has an MSc in Chemistry, and a PhD in Biochemistry & Biophysics from Karolinska Institutet. Peter has conducted research as a guest researcher at Yale University (USA), Kyoto University (Japan) and at Institut Curie (France). He is an expert in strategic IP counselling for life science companies, and acts as a board member and advisor in a number of Scandinavian pharmaceutical companies.
Anna-Lena Sventelius BOARD MEMBER
Anna-Lena Sventelius who is the daughter of Arne Holmgren has almost 30 years experience of journalistic publishing. Anna-Lena began her career working as a reporter for national magazines before continuing to work as an editor in chief and publishing director at LRF Media and Bonnier Magazines & Brands. She is current editor in chief and publisher of the magazine Lantliv (141 000 readers).
“Our father Arne Holmgren really lived for his science. Me and my brother Magnus are very happy to be able to run Arne’s patents and company, Thioredoxin Systems AB, together with a very competent group of people.”
Magnus Holmgren CHAIRMAN
Magnus Holmgren is the son of Professor Holmgren and has worked in development of telecom systems for over 20 years. Magnus was a pioneer in the development of mobile data in radio access networks. Magnus is currently involved in the development of 4G and 5G telecom systems at Ericsson. Magnus has more than 15 years of experience in line management.
“Resistant bacteria is a big threat against the humanity. If our father Arne Holmgren’s science can contribute to a solution, me and my sister Anna-Lena would both be incredibly proud.”